The Chan Zuckerberg Initiative has announced a ten-year commitment focused on accelerating biomedical science and advancing human health.

Announced five years after the launch of the Chan Zuckerberg Initiative’s science program — with the mission to support the science and technology that will make it possible to cure, prevent, or manage all disease by the end of the century — the initiative will focus on developing new research, institutes, and technologies to measure and observe human biology to help deepen our understanding of human health and disease. CZI spokesperson Jeff MacGregor told the Associated Press that investments will total up to $3.4 billion. In addition to expanding support for its science and science technology programs, CZI will invest between $600 million and $900 million, according to the AP, to create the Chan Zuckerberg Institute for Advanced Biomedical Imaging as an extension of the CZI Imaging program to ensure broad access to new technologies through a visiting scientists program and the dissemination of tools. Another $1 billion will launch the Chan Zuckerberg Biohub Network, in which Biohubs will be created with the goal of pursuing scientific challenges on fifteen-year time horizons, while an additional $800 million to $1 billion will extend through 2031 the operations of the Chan Zuckerberg Biohub, which brings together scientists and engineers from Stanford University; University of California, Berkeley; and University of California, San Francisco.

In addition, CZI has committed $500 million over fifteen years to establish the Kempner Institute for the Study of Natural and Artificial Intelligence at Harvard University. The gift will support ten new faculty appointments, new computing infrastructure, and other resources that will enable students to flow between labs at the intersection of neuroscience and artificial intelligence. The institute’s name honors Mark Zuckerberg’s mother, Karen Kempner Zuckerberg, and her parents, Sidney and Gertrude Kempner. Scheduled to open by the end of 2022, the institute will recruit and train future leaders and researchers through funding dedicated to supporting undergraduate and graduate students as well as postdoctoral fellows.

“Biomedical science and technology development hold tremendous promise to advance human health and treat disease,” said CZI co-founder and co-CEO Priscilla Chan. “Working as partners with scientists, patients, and open source communities, we’ve learned so much during these first five years of our science journey about where we can have the best impact in accelerating biomedicine. Now we’re ready to begin our next chapter. In addition to expanding our support for our core scientific programs in neurodegeneration, single-cell biology, imaging, open science, rare disease research, and infectious disease research, over the next ten years, CZI Science will focus on building new tools and technologies to measure human biology in action to benefit human health.”